Pratik Shah, Ph.D.
joined Thomas, McNerney & Partners in 2004 and represents Thomas, McNerney & Partners on the boards of
, and SGB, Inc.
He was also a board member at CNS Therapeutics, Inc.
prior to its acquisition in 2012, and
Ocera Therapeutics, Inc. (OCRX)
joining the firm, he was the Chief Business Officer and co-founder of Kalypsys, Inc., a biopharmaceutical company focused on the discovery and
clinical development of new medicines for cancer, inflammation and metabolic
disease using its proprietary automation technologies. Before co-founding Kalypsys, Pratik was at McKinsey &
Company, where he focused on biotechnology and venture capital projects. He
was formerly a co-founder and VP of Operations at NephRx Corporation, a
start-up company focused on the discovery of therapeutic proteins for renal
disease. Pratik holds a B.S. in Biological Sciences from the University of
California at Irvine and both a Ph.D. in Biochemistry & Molecular Biology
and an M.B.A. from the University of Chicago.